Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: Preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial
    Meeting Abstract

    Hyman, D. M.; Piha-Paul, S. A.; RodoĢn, J.; Saura, C.; Puzanov, I.; Shapiro, G. I.; Loi, S.; Joensuu, H.; Hanrahan, A. J.; Modi, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Treatment outcomes in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast MR imaging: Results of a secondary analysis of TBCRC 017
    Meeting Abstract

    Hyslop, T.; Alvarado, M.; Forero, A.; Golshan, M.; Hieken, T.; Horton, J.; Hudis, C.; McGuire, K.; Meric-Bernstam, F.; Nanda, R.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab in the treatment of metastatic HER2-positive breast cancer after prior trastuzumab/pertuzumab- or pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Argolo, D.; Smyth, L.; Chen, M. F.; Hudis, C. A.; Dang, C. T.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Androgen receptor (AR) mutations in a cohort of patients with breast cancer (BC) who have undergone tumor genomic profiling
    Meeting Abstract

    Gucalp, A.; Proverbs-Singh, T. A.; Razavi, P.; Chandarlapaty, S.; Patil, S.; Ross, D. S.; Zehir, A.; Baselga, J.; Hudis, C. A.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Sugarman, S.; Jones, L.; Boafo, C.; Patil, S.; Schweber, S.; Yu, A.; Argolo, D.; Modi, S.; Iyengar, N.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2- advanced breast cancer
    Meeting Abstract

    Bardia, A.; Modi, S.; Oliveira, M.; Campone, M.; Ma, B.; Dirix, L.; Weise, A.; Nardi, L.; Zhang, V.; Bhansali, S. G.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Safety and efficacy of anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in heavily pretreated patients with TNBC
    Meeting Abstract

    Bardia, A.; Diamond, J. R.; Mayer, I. A.; Starodub, A. N.; Moroose, R. L.; Isakoff, S. J.; Ocean, A. J.; Guarino, M. J.; Berlin, J. D.; Messersmith, W. A.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage breast cancer
    Meeting Abstract

    Cadoo, K.; Kaufman, P. A.; Hudis, C.; Chang, C.; Berrak, E.; Song, J.; Seidman, A. D.; Traina, T. A.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Program evaluation of a female sexual medicine and women's health program
    Meeting Abstract

    Carter, J.; Seidel, B.; Stabile, C.; Baser, R.; Eaton, A.; Goldfarb, S.; Goldfrank, D.
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Optimization of intermittent high dose lapatinib administration with or without capecitabine: A rational approach to drug dosing and scheduling using Norton-Simon modeling
    Meeting Abstract

    Morikawa, A.; De Stanchina, E.; Patil, S.; Chandarlapaty, S.; Li, B. T.; Norton, L.; Seidman, A. D.
    Cancer Research (2016)

    Fulltext@MSK | Save